https://scholars.lib.ntu.edu.tw/handle/123456789/473599
標題: | Prognostic factors in extrapulmonary small cell carcinomas: A large retrospective study | 作者: | Lin Y.-L. Chung C.-Y. Chang C.-S. Wu J.-S. KUAN-TING KUO SUNG-HSIN KUO ANN-LII CHENG |
公開日期: | 2008 | 卷: | 72 | 期: | 3-4 | 起(迄)頁: | 181-187 | 來源出版物: | Oncology | 摘要: | Background: Extrapulmonary small cell carcinoma (EPSCC) is a heterogeneous group of cancers. The clinicopathological features of EPSCC remain poorly defined. Patients and Methods: Patients with the clinicopathological features of EPSCC, treated at three major medical centers in Taiwan, were included. Histologic and clinical diagnoses, smoking history, staging, clinical course and treatment outcome were reviewed and analyzed. Results: A total of 90 patients, treated between 1995 and 2005, were eligible for analysis. Forty-nine patients had limited disease and 41 extensive disease. Ten, 18, 17 and 45 patients received no treatment, local treatment, chemotherapy alone or combined modality treatment, respectively; the median survival for these four groups was 1.1, 13.8, 6.7 and 24.9 months. The origin of cancer was head and neck in 17, gastrointestinal in 27, genitourinary in 10, gynecologic in 27 and unknown in 9 patients; the median survival time was 34.2, 6.4, 9.1, 23.7 and 9.2 months, respectively. Ten out of 90 patients were long-term survivors, and 9 of them had tumors of head-and-neck and gynecologic origin. There was no statistically significant difference in survival between smokers and non-smokers. Factors associated with survival in univariate analysis included age ?60, female gender, limited disease, head-and-neck and gynecologic origin, as well as combined modality treatment. However, in multivariate analysis, only female gender, limited disease and combined modality treatment were independent predictors of survival. Conclusions: Female gender, limited disease and combined modality treatment are favorable prognostic factors for patients with EPSCC. Prolonged survival is more likely in patients with tumors of head-and-neck and gynecologic origin. Copyright ? 2007 S. Karger AG. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-38549158089&doi=10.1159%2f000112804&partnerID=40&md5=60984ebdd4301ca2510552aa0d3d425e https://scholars.lib.ntu.edu.tw/handle/123456789/473599 |
ISSN: | 0030-2414 | DOI: | 10.1159/000112804 | SDG/關鍵字: | anthracycline; antineoplastic agent; bleomycin; cisplatin; cyclophosphamide; doxorubicin; epirubicin; etoposide; fluorouracil; folinic acid; ifosfamide; paclitaxel; platinum; taxane derivative; vincristine; adult; aged; article; cancer chemotherapy; cancer radiotherapy; cancer surgery; cancer survival; combination chemotherapy; controlled study; digestive system cancer; disease severity; female; gynecologic cancer; head and neck cancer; human; major clinical study; male; monotherapy; multimodality cancer therapy; priority journal; prognosis; radiation dose; small cell carcinoma; Taiwan; treatment outcome; urogenital tract cancer; Carcinoma, Small Cell; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。